KDR and neoplasm: Since migrating cancer cells produce high levels of vascular endothelial growth factor (VEGF), a secreted angiogenic mitogen that promotes angiogenesis and tumor vascularization, vascular endothelial growth factor receptor (VEGFR) inhibitors are a particularly promising class of targeted therapy [[2], [3], [4], [5]].